DE60118953D1 - Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung - Google Patents

Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung

Info

Publication number
DE60118953D1
DE60118953D1 DE60118953T DE60118953T DE60118953D1 DE 60118953 D1 DE60118953 D1 DE 60118953D1 DE 60118953 T DE60118953 T DE 60118953T DE 60118953 T DE60118953 T DE 60118953T DE 60118953 D1 DE60118953 D1 DE 60118953D1
Authority
DE
Germany
Prior art keywords
treatment
inflammatory
hemmer
endurance
protein transferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60118953T
Other languages
English (en)
Other versions
DE60118953T2 (de
Inventor
William End
Ronald Bowden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE60118953D1 publication Critical patent/DE60118953D1/de
Application granted granted Critical
Publication of DE60118953T2 publication Critical patent/DE60118953T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60118953T 2000-11-28 2001-11-20 Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung Expired - Lifetime DE60118953T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25334600P 2000-11-28 2000-11-28
US253346P 2000-11-28
PCT/EP2001/013540 WO2002043733A1 (en) 2000-11-28 2001-11-20 Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease

Publications (2)

Publication Number Publication Date
DE60118953D1 true DE60118953D1 (de) 2006-05-24
DE60118953T2 DE60118953T2 (de) 2007-01-11

Family

ID=22959893

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60118953T Expired - Lifetime DE60118953T2 (de) 2000-11-28 2001-11-20 Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung

Country Status (11)

Country Link
US (1) US20040044032A1 (de)
EP (1) EP1339407B1 (de)
JP (1) JP4231691B2 (de)
AT (1) ATE323490T1 (de)
AU (1) AU2002218311A1 (de)
CY (1) CY1106122T1 (de)
DE (1) DE60118953T2 (de)
DK (1) DK1339407T3 (de)
ES (1) ES2261523T3 (de)
PT (1) PT1339407E (de)
WO (1) WO2002043733A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089502A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
EP1732549A4 (de) * 2004-03-18 2009-11-11 Brigham & Womens Hospital Verfahren zur behandlung von synucleinopathien
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089504A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
PT1815247E (pt) 2004-11-05 2013-04-23 Janssen Pharmaceutica Nv Uso terapêutico de inibidores de farnesiltransferase e métodos para monitorizar a eficácia do mesmo
WO2007075923A2 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
JP2012508768A (ja) * 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション アザキノリノン誘導体及びその使用
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
CN105073729A (zh) 2012-10-16 2015-11-18 詹森药业有限公司 RORγt的苯基连接的喹啉基调节剂
PL2909192T3 (pl) 2012-10-16 2017-09-29 Janssen Pharmaceutica Nv Połączone metylenem modulatory chinolinylowe ROR-GAMMA-T
KR20150070348A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
WO2015057626A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv QUINOLINYL MODULATORS OF RORyT
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
WO2015057629A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv ALKYL LINKED QUINOLINYL MODULATORS OF RORyt
DK3277842T5 (da) 2015-08-17 2020-08-31 Kura Oncology Inc Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
KR20190082247A (ko) 2016-11-03 2019-07-09 쿠라 온콜로지, 인크. 파르네실전달효소 억제제를 이용하여 암 환자를 치료하는 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646154A (en) * 1992-10-07 1997-07-08 Sumitomo Pharmaceuticals Co., Ltd. Pharmaceutical compositions for inhibiting the formation of tumor necrosis factor
US5470832A (en) * 1994-01-31 1995-11-28 Merck & Co., Inc. Inhibitors of geranylgeranyl-protein transferase
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
TW316902B (de) * 1994-12-28 1997-10-01 Janssen Pharmaceutica Nv
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
ES2175137T3 (es) * 1995-12-08 2002-11-16 Janssen Pharmaceutica Nv Derivados de (imidazol-5-il)metil-2-quinolinona como inhibidores de laproteina farnesil-transferasa.
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5929077A (en) * 1996-11-08 1999-07-27 Leftheris; Katerina Thioproline-containing inhibitors of farnesyl protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
GB2323783A (en) * 1997-04-02 1998-10-07 Ferring Bv Group Holdings Inhibitors of farnesyl protein transferase
DE69838025T2 (de) * 1997-04-25 2008-05-08 Janssen Pharmaceutica N.V. Chinazolinone die farnesyltransferase hemmen
TW527355B (en) * 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
EE04962B1 (et) * 1998-12-23 2008-02-15 Janssen Pharmaceutica N.V. Kinoliini ühend, seda sisaldav farmatseutiline kompositsioon, ühendi kasutamine ravimina ning meetod ühendi ja kompositsiooni valmistamiseks

Also Published As

Publication number Publication date
PT1339407E (pt) 2006-08-31
US20040044032A1 (en) 2004-03-04
EP1339407A1 (de) 2003-09-03
ATE323490T1 (de) 2006-05-15
JP4231691B2 (ja) 2009-03-04
JP2004514695A (ja) 2004-05-20
ES2261523T3 (es) 2006-11-16
DK1339407T3 (da) 2006-08-14
EP1339407B1 (de) 2006-04-19
CY1106122T1 (el) 2011-06-08
WO2002043733A1 (en) 2002-06-06
AU2002218311A1 (en) 2002-06-11
DE60118953T2 (de) 2007-01-11

Similar Documents

Publication Publication Date Title
DE60118953D1 (de) Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung
CY1105477T1 (el) Αναστολεις τρανσφepασης φαρνεσυλ πρωτεϊνης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60335560D1 (de) Zusammensetzungen enthaltend zitronensäure zur behandlung von nagelpilzerkrankungen
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
DE60124576D1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
EA200601239A1 (ru) Замещённые хинолиновые соединения
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
NO20063064L (no) Ny anvendelse av peptidforbindelser for behandling av sentralneurotisk smerte
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
TNSN06138A1 (fr) Inhibitors of the mutant form of kit
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
EA200401183A1 (ru) Применение ингибиторов il-18 в качестве диагностического маркера
ATE338036T1 (de) Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
ATE469886T1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
ATE290384T1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
ATE503476T1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
ATE330938T1 (de) Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
ATE308513T1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente

Legal Events

Date Code Title Description
8364 No opposition during term of opposition